OREANDA-NEWS. June 17, 2016. The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies, today announced the results of the Annual General Shareholders’ Meeting (AGM) held on June 16, 2016 in Moscow.

Voting at the AGM, shareholders adopted, among others, the following decisions:

  • Shareholders approved HSCI’s Annual Report and Annual Financial Statements prepared according to Russian Accounting Standards, including the Company’s profit and loss statement, for the 2015 fiscal year.
  • Shareholders decided to allocate the Company’s 2015 net profit of RUB 9,086,000 as well as retained earnings from previous years of RUB 13,414,000 to pay annual dividends.
    Therefore, the total amount of the approved dividends for 2015 is RUB 22.500 million (including the Company’s FY2015 net profit and retained earnings from previous years under RAS). The annual dividends were declared as RUB 0.30 per ordinary share. Shareholders of record on June 30, 2016 will be entitled to receive dividends for 2015.
  • Shareholders elected a new Board of Directors, which includes the following directors, 4 of which are independent:
    1. Dmitry Alexandrov, Deputy General Director for Investments, UNIVER Capital; independent director;
    2. Roman Deev, Chief Scientific Officer of HSCI;
    3. Artur Isaev, General Director of HSCI;
    4. Sergey Kiselev, Head of the Lab at the Federal scientific-clinical center of physical-chemical medicine, independent director;
    5. Boris Maizel, independent director;
    6. Konstantin Mauer, Director of Mauer-Audit auditing company LLC; independent director;
    7. Alexander Prikhodko, Deputy General Director of HSCI.

According to HSCI’s Charter, the Company’s Board of Directors consists of 7 members.

  • Members of the Audit Commission were elected:
  1. Svetlana Blokhina, Financial Control and Internal Audit Officer of HSCI;
  2. Oksana Peterson, Deputy Chief accountant of HSCI;
  3. Svetlana Samoylova, Director for Investor Relations of HSCI.

According to HSCI’s Charter, the Company’s Audit Commission consists of 3 members.

  • Shareholders approved ReKa-Audit LLC (Moscow region) as HSCI’s external auditor for the 2016 fiscal year.

Human Stem Cells Institute PJSC (HSCI, www.eng.hsci.ru) is a Russian public biotech company founded in 2003.

HSCI engages in R&D as well as commercialization and marketing of innovative proprietary products and services in the field of  regenerative medicine, bio-insurance, medical genetics including reproductive genetics, gene therapy and biopharmaceutics (within the international SynBio project).

The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine. 

HSCI owns the largest family cord blood stem cell bank in Russia – Gemabank®, as well as the reproductive cell and tissue bank Reprobank® (personal storage and donation).

The Company launched Neovasculgen®, the first-in-class gene-therapy drug for treating Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

HSCI is implementing a socially significant Genetico® project for the development of its own medical center & testing lab to provide a range of genetic diagnostic and consulting services with the aim of early identification, prediction and prophylactic treatment of genetic disorders (incl. PGD, NIPT, Oncogenetics, Bioinformatics).

The Company actively promotes its products and services on the Russian market and intends to open new markets throughout the world. 

HSCI is a co-investor in SynBio – a long-term multilateral project to create new unique medicines (first-in-class and BioBetters) for the Russian and international markets. The SynBio project, supported by an investment from RUSNANO, unites top Russian and international companies engaged in biotech/biopharm R&D.

HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker: ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.